Loading
Life sciences · Journal article
Cell Death Discovery · September 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Acute myeloid leukemia (AML) is a highly heterogeneous and extremely aggressive form of blood cancer. Despite recent advances, AML continues to be a challenging disease to treat; the overall prognosis and response to therapy are strongly influenced by karyotypic and molecular alterations [ 1 ]. Mutations of the Tp53 gene ( TP53 mut ) are among the most common alterations found in human malignancies, affecting 5–20% of de novo AML and more frequently (up to 37%) observed in patients with therapy-related AML [ 1, 2 ]. The TP53 mut AML has also been associated with a lower response to conventional chemotherapies, high relapse, and inferior overall survival [ 2, 3, 4 ]. Since 2017, the Food and Drug Administration (FDA) has approved several new drugs for AML [ 1 ], but treating TP53 muts AML remains a formidable challenge.